Many now are undergoing treatments for Coronavirus infection is a known fact. Now, the World Health Organization or WHO has given approval to 2 new medicines to treat these patients.
The medicines from the USA based Elli Lilly and Company and UK based GlaxoSmithKline have been given approval by WHO. It is important to note that WHO has given approval to the monoclonal drugs for monoclonal antibodies developed by the Glaxo SmithKline for treating especially rheumatoid arthritis. This superb drug Baricitinib or Olumiant from Glaxo SmithKline would not only save the lives of Coronavirus infected persons but also make the use of ventilators unnecessary.
The superb point is that this new drug (developed to treat joint pain) along with steroids would give great results. Since the month of May in 2021, this drug has been in use in the USA and in Europe to treat Covid-19 patients. The Glaxo SmithKline Company had announced that it would be providing monoclonal antibody therapy for those persons affected with Coronavirus and admitted in the hospitals. It must not be forgotten that another monoc;lonal antibody developed by Regeneron Pharmaceuticals Inc got the approval from WHO in 2021 for treating Covid-19 infected persons. The doctors now want this drug Baricitinib to be available for the poor sections of the society.